Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
79,963,455
-
Total 13F shares
-
11,812,270
-
Share change
-
-786,677
-
Total reported value
-
$75,222,311
-
Price per share
-
$6.36
-
Number of holders
-
66
-
Value change
-
-$8,416,035
-
Number of buys
-
30
-
Number of sells
-
34
Institutional Holders of Niagen Bioscience, Inc. - Common Stock (NAGE) as of Q4 2025
As of 31 Dec 2025,
Niagen Bioscience, Inc. - Common Stock (NAGE) was held by
66 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,812,270 shares.
The largest 10 holders included
VANGUARD GROUP INC, Tieton Capital Management, LLC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, Connor, Clark & Lunn Investment Management Ltd., JPMORGAN CHASE & CO, Bank of New York Mellon Corp, GABELLI FUNDS LLC, and NAVELLIER & ASSOCIATES INC.
This page lists
66
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.